Fig. 8. MYG1 correlates with an active glycolysis pathway in CRC patients and tumor model.
a–c MYG1, PKM2 and c-Myc protein levels were evaluated by IHC staining in specimens of CRC patients from NF-PET cohort (n = 43) and followed by quantification. Representative images of PET/CT and IHC staining (a). The areas marked by squares were magnified. Scale bar, 100 μm (insets). The correlations between the level of MYG1 and SUVmax, the level of PKM2 and c-Myc were analyzed (b). The protein levels of MYG1, PKM2, c-Myc in tumor and normal mucosa (c). d, e Expression of MYG1, PKM2, c-Myc, Ki-67 in tumor tissues from orthotopic CRC models were evaluated by IHC and apoptosis evaluated by TUNEL staining (d), and quantified (e) (n = 5 per group). The areas marked by squares were magnified. Scale bar, 200 μm (in IHC), and 100 μm (in IF). f Work model for MYG1 driving glycolysis and CRC development. Two-sided Pearson correlation (b). Unpaired two-sided Student’s t-test (c). One-way ANOVA, Dunnett’s multiple comparisons test (e). p value was provided in the figure. Representative results were shown (a and d). Error bars, mean ± SD. Source data are provided as a Source Data file.